Artelo Biosciences (ARTL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Jul, 2026Executive summary
Annual meeting scheduled for July 17, 2026, with voting open until July 16, 2026.
Shareholders of record as of May 22, 2026, are eligible to vote on key matters.
Voting can be conducted online, by phone, or at the virtual meeting.
Voting matters and shareholder proposals
Shareholders are encouraged to vote on important issues impacting their investment.
Voting instructions and access to proxy materials have been provided to eligible shareholders.
Shareholder rights and capital structure
Only holders of common shares as of the record date are entitled to vote.
Each shareholder receives a unique control number to access voting and meeting materials.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Artelo Biosciences
- Phase II data show significant weight gain in cancer anorexia; glaucoma trial results expected soon.ARTL
H.C. Wainwright 28th Annual Global Investment Conference - Lead drug candidates show clinical promise in major markets, backed by robust patents and expertise.ARTL
Corporate presentation - Net loss narrowed, cash improved with $11M financing, but future depends on new funding.ARTL
Q2 2026 - All proposals, including director elections and share increases, were approved.ARTL
AGM 2026 - Shareholders urged to vote before July 17, 2026, to ensure quorum and efficient meeting conduct.ARTL
Proxy filing - Shareholders will vote on director elections, share authorization, and a major equity issuance.ARTL
Proxy filing - Multiple clinical milestones expected in the next 18 months across a diverse therapeutic pipeline.ARTL
H.C. Wainwright 26th Annual Global Investment Conference 2024 - Shareholders will vote on director elections, a large share increase, and a major equity issuance.ARTL
Proxy filing - Lead drug candidates advance in cancer, pain, and anxiety with strong safety and efficacy data.ARTL
Corporate presentation